國立高雄大學圖資館 |

Language: English

Back

Current advances in osteosarcomaclin...

Gorlick, Richard.

Current advances in osteosarcomaclinical perspectives : past, present and future /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Current advances in osteosarcomaedited by Eugenie S. Kleinerman, Richard Gorlick.
Reminder of title:	clinical perspectives : past, present and future /
other author:	Kleinerman, Eugenie S.
Published:	Cham :Springer International Publishing :2020.
Description:	xiii, 212 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Osteosarcoma.
Online resource:	https://doi.org/10.1007/978-3-030-43032-0
ISBN:	9783030430320$q(electronic bk.)

Current advances in osteosarcomaclinical perspectives : past, present and future /
Current advances in osteosarcomaclinical perspectives : past, present and future /[electronic resource] :edited by Eugenie S. Kleinerman, Richard Gorlick. - Second edition. - Cham :Springer International Publishing :2020. - xiii, 212 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.12570065-2598 ;. - Advances in experimental medicine and biology ;946..

Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective -- Part 1: Surgical Considerations and Outcomes -- Limb Salvage and Reconstruction Options in Osteosarcoma -- Advances in the functional assessment of patients with sarcoma -- Part II: Novel Therapeutic Approaches Based on Biology -- Radiopharmaceuticals for Treatment of Osteosarcoma -- HER-2 Targeted Therapy in Osteosarcoma -- Aerosolized Chemotherapy for Osteosarcoma -- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma -- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease -- Using liquid biopsy in the treatment of patient with osteosarcoma -- Part III: Novel Immunotherapeutic Approaches -- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020's -- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma -- Natural Killer Cell Immunotherapy for Osteosarcoma -- Nanocapsule delivery of IL-12 -- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy -- Part IV: Survivorship and Late Effects -- Editorial Comments on late effects -- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention -- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors -- Index.

This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.

ISBN: 9783030430320$q(electronic bk.)

Standard No.: 10.1007/978-3-030-43032-0doiSubjects--Topical Terms:

682735
Osteosarcoma.

LC Class. No.: RC280.B6 / C877 2020

Dewey Class. No.: 616.99471

Current advances in osteosarcomaclinical perspectives : past, present and future /
LDR:03732nmm a2200349 a 4500 001 579406
003 DE-He213
005 20200922111149.0
006 m
007 cr
008 201229s2020
020 $a 9783030430320$q(electronic bk.)
020 $a 9783030430313$q(paper)
024 7 $a 10.1007/978-3-030-43032-0 $2 doi
035 $a 978-3-030-43032-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B6 $b C877 2020
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.99471 $2 23
090 $a RC280.B6 $b C976 2020
245 0 0 $a Current advances in osteosarcoma $h [electronic resource] : $b clinical perspectives : past, present and future / $c edited by Eugenie S. Kleinerman, Richard Gorlick.
250 $a Second edition.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a xiii, 212 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.1257
505 0 $a Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective -- Part 1: Surgical Considerations and Outcomes -- Limb Salvage and Reconstruction Options in Osteosarcoma -- Advances in the functional assessment of patients with sarcoma -- Part II: Novel Therapeutic Approaches Based on Biology -- Radiopharmaceuticals for Treatment of Osteosarcoma -- HER-2 Targeted Therapy in Osteosarcoma -- Aerosolized Chemotherapy for Osteosarcoma -- The Histone Deacetylase inhibitor Entinostat/Syndax 275 in Osteosarcoma -- Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease -- Using liquid biopsy in the treatment of patient with osteosarcoma -- Part III: Novel Immunotherapeutic Approaches -- Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020's -- Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma -- Natural Killer Cell Immunotherapy for Osteosarcoma -- Nanocapsule delivery of IL-12 -- Discovery of cell surface vimentin (CSV) as a sarcoma target and development of CSV-targeted IL-12 immune therapy -- Part IV: Survivorship and Late Effects -- Editorial Comments on late effects -- Anthracycline-Induced Cardiotoxicity: Causes, mechanisms & prevention -- Exercise and Physical Activity in Patients with Osteosarcoma and Survivors -- Index.
520 $a This thoroughly revised second edition complied in 2 books is an up-to-date overview of the current clinical advances in sarcoma and osteosarcoma. The new edition features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, these essential volumes also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists focused in sarcoma.
650 0 $a Osteosarcoma. $3 682735
650 1 4 $a Cancer Research. $3 273660
650 2 4 $a Medical Microbiology. $3 273931
650 2 4 $a Cell Biology. $3 274165
650 2 4 $a Pediatrics. $3 274247
700 1 $a Kleinerman, Eugenie S. $3 868781
700 1 $a Gorlick, Richard. $3 868782
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 557559
856 4 0 $u https://doi.org/10.1007/978-3-030-43032-0
950 $a Biomedical and Life Sciences (Springer-11642)